Literature DB >> 7908586

Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.

C M Masimirembwa1, I Johansson, J A Hasler, M Ingelman-Sundberg.   

Abstract

The objective of this study was to determine the CYP2D6 genotype of a black Zimbabwean population. Genotyping was carried out using Eco RI and Xba I RFLP, and allele-specific PCR amplification. Of 114 Zimbabwean samples analysed, no individual homozygous for any of the defect allelic forms CYP2D6A, CYP2D6B or CYP2D6D or combinations thereof was found. The allele frequencies of the three defect genes were 0, 1.8 and 3.9%, respectively. No subject carrying the Xba I 44 kb haplotype, indicative for poor metabolizers among Caucasians, was identified, whereas five individuals being heterozygous with a 29/42 kb haplotype were seen. Three out of the four CYP2D6B alleles found were associated with the 29/42 kb haplotype. Our findings are in agreement with the 0-2% prevalence of poor metabolizers (PMs) in the black populations previously phenotyped. The very low frequency of the CYP2D6B allele in the Zimbabwean population is different from very recent data from black Americans (allele frequency = 8.5%) and might indicate the Caucasian ancestry of this allele. Taken together, our data indicate important interethnic differences in the CYP2D locus between Caucasian, Asian and different black populations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7908586     DOI: 10.1097/00008571-199312000-00001

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  13 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Authors:  K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

3.  CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.

Authors:  S Panserat; L Sica; N Gérard; H Mathieu; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 4.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

5.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

Authors:  C Sachse; J Brockmöller; S Bauer; I Roots
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

6.  A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency.

Authors:  F Broly; D Marez; J M Lo Guidice; N Sabbagh; M Legrand; P Boone; U A Meyer
Journal:  Hum Genet       Date:  1995-11       Impact factor: 4.132

7.  Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.

Authors:  O O Simooya; G Sijumbil; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

Review 8.  Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.

Authors:  Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2022-06-21

9.  Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society.

Authors:  Vural Ozdemir; Guilherme Suarez-Kurtz; Raphaëlle Stenne; Andrew A Somogyi; Toshiyuki Someya; S Oğuz Kayaalp; Eugene Kolker
Journal:  OMICS       Date:  2009-02

Review 10.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.